article · Vaccine
The abstract on record is too brief for a reliable plain-language summary, so none has been generated.
Our findings suggest that South Africa's COVID-19 vaccination programme represented good value for money in the first two years of rollout.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.vaccine.2024.05.036
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
